RI Bio, Rhode Island’s premier life sciences professional trade organization, has announced the appointment of Glenn Robertelli as their new Executive Director, effective July 1, 2024. Robertelli brings over 25 years of international experience in the technology, medical, and consumer products industries, marking a significant milestone for RI Bio as they continue to drive innovation and growth in the life sciences sector. Most recently he served as the co-founder and Chief Operating Officer (COO) at Admetsys and has been instrumental in driving the convergence of biosensors, Artificial Intelligence, patient-specific metabolic modeling and automated drug delivery. Under his leadership, Admetsys developed a real-time diagnostics and clinical robotics platform using artificial intelligence and biosensors to optimize patient outcomes. This platform, often referred to as an artificial pancreas or Automated Insulin Delivery System, reads blood analytes in real-time, creates patient-specific metabolic models, and manages patient glucose levels automatically. The system has been approved in Europe and successfully completed three FDA clinical trials in the USA under Breakthrough Device Designation. Robertelli’s extensive expertise is recognized globally, having been named Entrepreneur of the Year by Entrepreneur Magazine and listed among the Top 10 Global Entrepreneurs by AskMen’s Magazine. He holds a patent for a System and Method for Clinical Quality and Safety Automation and has a proven track record in business strategy, innovation, and entrepreneurship. Before Admetsys, Robertelli was the founder and CEO of Intelligen LLC and Intelligen (Asia-Pacific) Ltd, where he led the development of ViewGuard® and GearGuard® products, now embedded in millions of mobile devices worldwide. He also graduated from Johnson & Johnson’s Leadership Development Program and worked extensively inside and outside the USA in roles including operations, supply chain, strategic marketing, M&A, and new product development. Jaimy Mauricio, MBA, RI Bio Board Chair and Senior Director of Finance at Intellia Therapeutics, said Robertelli brings a long track record and vast expertise as a life sciences entrepreneur to RI Bio and the greater RI life sciences community. “The Board chose Glenn because of his dedication to building high-performing teams and ecosystems and excellent strategic plan for the organization. We are excited to have a professional of his caliber, and we look forward to his contributions and insights. We anticipate many exciting developments in the years ahead as we continue to grow the state’s life sciences economy.” Robertelli shared his vision for RI Bio. “I’m excited for the opportunity to lead RI Bio through its next phase of growth. Our industry stands at the forefront of groundbreaking advancements that have the potential to transform lives. I am committed to fostering innovation, collaboration and growth within Rhode Island’s life sciences sector, ensuring that we lead in scientific excellence and patient safety while increasing the sector’s economic impact.” With Robertelli at the helm, RI Bio is poised for a new era of leadership and innovation, driving the Rhode Island life sciences sector forward.